Additionally, the concomitant administration of anti-CTLA4 and anti-CD154 mAbs was shown to delay SLE onset in NZB/W F1 lupus-prone mice and even to prolong the survival of previously treated mice with more advanced states of the disease [89]. Here, CTLA4 is linked to systemic lupus erythematosus.